However, previous reports suggest that mepolizumab is more effective in ANCA-negative cases and less effective in ANCA-positive cases [14], and MPO-ANCA positivity is considered a risk factor for EGPA relapse [3]. Here, MPO is linked to eosinophilic granulomatosis with polyangiitis.